hotspot -WSS

hotspot

author：leisure time 2025-09-29 00:38:38 - browse：3886

A new asthma treatment that could be administered just once every six months has succeeded in two Phase 3 trials, developer GlaxoSmithKline announced Tuesday.

The drug, depemokimab, is designed to treat asthma by targeting a protein called interleukin-5, or IL-5. The protein is linked to the type of inflammation found in most severe asthma cases, according to the pharma company.

Depemokimab hit its primary endpoints in the trials, reducing asthma attacks over a year’s time frame. The company didn’t disclose exact details from the SWIFT-1 and SWIFT-2 trials.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Medical school prerequisites are outdated

focus

WSS

Will General Catalyst be the first of many hospital takeovers?

Removing probiotics from the NICU could threaten preemies' health

AstraZeneca CEO says participant had neurological symptoms, could be discharged today

Medicare will require more price transparency from hospitals

Healthy food access boosts outcomes in two studies

FDA cancer chief on how to get things done: ‘Don’t tell anybody'

hotspot

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

Medical leaders decry Supreme Court decision on affirmative action

Medical school prerequisites are outdated

Anesthesiologist group: stop taking Ozempic before surgery

Free speech concerns arise in wake of journal editor Eisen's firing

Hepatitis C has a cure — but many Americans still lack access to it

Don't let 'shelved assets' gather dust. Make them into new lifesaving drugs

Hepatitis C has a cure — but many Americans still lack access to it

A clever new way to fix Medicaid and graduate medical education

In age of alternative facts, a scholarly course on calling out crap

Readout Newsletter: Zepbound, Valneva's vaccine, and more

knowledge

Readout Newsletter: Novo Nordisk trial, Verve base editing, etc

White House calls on federal agencies to crack down on AI abuses

Medicare solvency divides Republicans at the presidential debate

How state and local governments are sidelining science

HPV cancer vaccine study demonstrates efficacy

More doctors should go into startup world

Wikipedia

Wikipedia

focus

focus